STOCK TITAN

Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) reported that Chief Commercial Officer Eric Warren exercised stock options and sold the resulting shares on August 21, 2026. He exercised 7,437 stock options at an exercise price of $13.24 per share into 7,437 shares of common stock, then sold 7,437 shares at a weighted‑average price of $25.9767 per share in multiple trades. Following the option exercise, he held 238,001 stock options directly. These transactions were effected pursuant to a Rule 10b5‑1 stock selling plan adopted on March 27, 2026.

Positive

  • None.

Negative

  • None.
Insider Warren Eric
Role Chief Commercial Officer
Sold 7,437 shs ($193K)
Approx. gross sale proceeds $193K
Approx. exercise cost $98K
Approx. pre-tax spread $95K
Type Security Shares Price Value
Exercise Stock Option F1, F3 7,437 $0.00 $0.00
Exercise Common Stock F1 7,437 $13.24 $98K
Sale Common Stock F1, F2 7,437 $25.9767 $193K
Holdings After Transaction: Stock Option — 238,001 shares (Direct); Common Stock — 38,400 shares (Direct)
Footnotes (3)
  1. F1. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.
  2. F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
  3. F3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Options exercised 7,437 shares Stock options exercised into common stock on August 21, 2026
Exercise price $13.24 per share Exercise price of stock option converted on August 21, 2026
Shares sold 7,437 shares Common shares sold on August 21, 2026 following option exercise
Weighted-average sale price $25.9767 per share Weighted-average price for 7,437 shares sold in multiple trades
Sale price range $25.82–$26.15 per share Price range of individual trades included in the weighted-average
Stock options held after transaction 238,001 options Directly held options following the reported exercise
Rule 10b5-1 plan adoption date March 27, 2026 Date on which the stock selling plan governing these trades was adopted
Option expiration date April 21, 2035 Expiration of the exercised stock option
Rule 10b5-1 stock selling plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 stock selling plan"
weighted-average price financial
"The price reported in Column 4 is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
stock option financial
"The stock option vested as to 25% of the underlying shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"with the remaining shares vesting in 36 substantially equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What insider transaction did MLYS report for Chief Commercial Officer Eric Warren?

Eric Warren exercised 7,437 stock options at $13.24 per share into 7,437 common shares and sold 7,437 shares on August 21, 2026 at a weighted‑average price of $25.9767 per share, all reported as direct holdings.

How many stock options does Eric Warren hold after the August 21, 2026 MLYS transactions?

After the August 21, 2026 transactions, Eric Warren held 238,001 stock options directly, according to the reported post‑transaction option balance.

At what prices were Eric Warren’s MLYS shares sold on August 21, 2026?

The reported price is a weighted‑average of $25.9767 per share. The 7,437 shares were sold in multiple transactions at prices ranging from $25.82 to $26.15 per share.

Were Eric Warren’s MLYS stock sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5‑1 stock selling plan adopted on March 27, 2026.

What are the terms of the MLYS stock option that Eric Warren exercised?

The exercised stock option had an exercise price of $13.24 per share and an expiration date of April 21, 2035. It vested 25% on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Warren Eric

(Last)(First)(Middle)
150 N. RADNOR CHESTER ROAD
SUITE F200

(Street)
RADNOR PENNSYLVANIA 19087

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/21/2026M(1)7,437A$13.2445,837D
Common Stock08/21/2026S(1)7,437D$25.9767(2)38,400D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$13.2408/21/2026M(1)7,437 (3)04/21/2035Common Stock7,437$0238,001D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.
2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Remarks:
/s/ Adam Levy, Attorney-in-fact08/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)